Search

Your search keyword '"Andreas Trumpp"' showing total 344 results

Search Constraints

Start Over You searched for: Author "Andreas Trumpp" Remove constraint Author: "Andreas Trumpp" Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
344 results on '"Andreas Trumpp"'

Search Results

1. Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response in pancreatic cancer

2. Multiple myeloma long-term survivors exhibit sustained immune alterations decades after first-line therapy

3. Mutation analysis in individual circulating tumor cells depicts intratumor heterogeneity in melanoma

4. Diagnostic leukapheresis reveals distinct phenotypes of NSCLC circulating tumor cells

5. Ferroptosis in health and disease

6. An arms‐race against resistance: leukemic stem cells and lineage plasticity

7. Protocol of the IntenSify‐Trial: An open‐label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab‐paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy

8. LRP8‐mediated selenocysteine uptake is a targetable vulnerability in MYCN‐amplified neuroblastoma

9. HAPLN1 potentiates peritoneal metastasis in pancreatic cancer

11. S123: ACUTE MYELOID LEUKEMIA STEM CELL SUBTYPES DEFINED BY MUTATIONS AND DIFFERENTIATION STATE REGULATE APOPTOTIC DEPENDENCY AND CLINICAL RESPONSE TO VENETOCLAX.

12. P1218: A REPROGRAMMING OF THE LYMPH NODE MICROENVIRONMENT UNDERLIES LOSS OF COMPARTMENTALISATION IN AGGRESSIVE LYMPHOMAS

13. PB1759: RETAINED FUNCTIONAL NORMAL AND/OR PRE-LEUKEMIC HSCS IN THE BONE MARROW ARE ASSOCIATED TO GOOD PROGNOSIS IN DNMT3AMUTNPM1MUT AML PATIENTS

14. P408: COMBINATORIAL BCL-2 FAMILY EXPRESSION IN ACUTE MYELOID LEUKEMIA STEM CELLS PREDICTS CLINICAL RESPONSE TO AZACITIDINE/VENETOCLAX

16. CRISPR-Cas9 mediated generation of a conditional poly(A) binding protein nuclear 1 (Pabpn1) mouse model reveals an essential role for hematopoietic stem cells

17. Clonal hematopoiesis with DNMT3A and PPM1D mutations impairs regeneration in autologous stem cell transplant recipients

18. Leukemic stem cells and therapy resistance in acute myeloid leukemia

19. Targeting the Leukemic stem cell protein machinery by inhibition of mitochondrial pyrimidine synthesis

20. Comparison of extraction methods for intracellular metabolomics of human tissues

21. Axon guidance receptor ROBO3 modulates subtype identity and prognosis via AXL-associated inflammatory network in pancreatic cancer

22. Identification of leukemic and pre-leukemic stem cells by clonal tracking from single-cell transcriptomics

23. Niche derived netrin-1 regulates hematopoietic stem cell dormancy via its receptor neogenin-1

24. Innovations, challenges, and minimal information for standardization of humanized mice

25. Metastasis-initiating cells induce and exploit a fibroblast niche to fuel malignant colonization of the lungs

26. Versatile workflow for cell type–resolved transcriptional and epigenetic profiles from cryopreserved human lung

27. Single cell polarity in liquid phase facilitates tumour metastasis

28. Screening drug effects in patient‐derived cancer cells links organoid responses to genome alterations

29. Survival of pancreatic cancer cells lacking KRAS function

30. Systemic Virus Infections Differentially Modulate Cell Cycle State and Functionality of Long-Term Hematopoietic Stem Cells In Vivo

31. Defined Conditions for the Isolation and Expansion of Basal Prostate Progenitor Cells of Mouse and Human Origin

32. Reduced hematopoietic stem cell frequency predicts outcome in acute myeloid leukemia

33. Transcriptome-wide Profiling and Posttranscriptional Analysis of Hematopoietic Stem/Progenitor Cell Differentiation toward Myeloid Commitment

34. Instruction of haematopoietic lineage choices, evolution of transcriptional landscapes and cancer stem cell hierarchies derived from an AML1‐ETO mouse model

35. An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imaging.

36. Estimating dormant and active hematopoietic stem cell kinetics through extensive modeling of bromodeoxyuridine label-retaining cell dynamics.

37. Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax

38. Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML

39. Recent advances in 'sickle and niche' research - Tribute to Dr. Paul S Frenette

40. MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis

41. Perivascular tenascin C triggers sequential activation of macrophages and endothelial cells to generate a pro-metastatic vascular niche in the lungs

42. Supplementary Figure 4 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax

43. Supplementary Figure 3 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax

44. Supplementary Figure 2 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax

45. Supplementary Figure 1 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax

46. SupplementaryFigure 6 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax

47. Supplementary Figure 7 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax

48. Data from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax

49. Supplementary Figure 5 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax

50. Supplementary Tables 1-7 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax

Catalog

Books, media, physical & digital resources